Overall the 5-year survival rate is around 54% in the United States. With high-dose therapy followed by ASCT, the median survival has been estimated in 2003 to be about 4.5 years, compared to a median around 3.5 years with "standard" therapy. The international staging system can help to predict survival, with a median survival (in 2005) of 62 months for stage-1 disease, 45 months for stage-2 disease, and 29 months for stage-3 disease. The median age at diagnosis is 69 years. Genetic testing SNP array karyotyping can detect copy number alterations of prognostic significance that may be missed by a targeted FISH panel.
Multiple myeloma
Monoclonal gammopathy of renal significance  Monoclonal gammopathy of renal significance  1
Monoclonal gammopathy of undetermined significance
Monoclonal gammopathy of renal significance
Smouldering myeloma
Waldenström macroglobulinemia
AL amyloidosis
Plasma cell leukemia